Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P).

CONCLUSIONS: Ixekizumab Q2W had higher efficacy at Week 52 compared to Q4W, with no increase in safety events. This article is protected by copyright. All rights reserved.
PMID: 29405255 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - February 6, 2018 Category: Dermatology Authors: Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P, IXORA-P investigators Tags: Br J Dermatol Source Type: research